Skip to main content

Table 3 Multivariate analysis of factors associated with DFS and OS

From: Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphobla stic leukemia

Variable

DFS

OS

HR

95% CI

P

HR

95% CI

P

non-IM use post-HCT

4.8

2.2-10.8

.000

6.2

2.6-15.0

.000

> CR1 pre-HCT

   

2.7

1.1-6.6

.023

BCR-ABL(+) pre-HCT

3.7

1.3-10.5

0.014

   
  1. IM, imatinib; HR, hazard ratio; CI, confidence interval.
Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us